This paper provides a comprehensive literature review of the combination of immune checkpoint inhibitors (ICIs) and chemotherapy drugs in the field of synergistic antitumor therapy, aiming to summarize and analyze the current status, key issues, and future trends of tumor chemotherapy combined with immunotherapy. Research indicates that chemotherapy drugs enhance the immune system's ability to recognize and kill tumors by inducing immunogenic cell death (ICD) and altering the tumor microenvironment (TME). This paper provides a detailed analysis of drug metabolism enzymes and transporters, time-dependent interactions, dual pathways for immune system activation, intrinsic sensitization of tumor cells, the microbiome-immunotherapy axis, mechanisms of resistance and reversal strategies, as well as breakthroughs in novel delivery systems. Finally, this paper discusses improvements and prospects for future immunotherapy-chemotherapy combination studies. Personalized dosing and toxicity management remain major challenges, and future efforts should focus on optimizing treatment regimens using multi-omics data and organoid/PDX models.
Yuan et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: